While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report. Pfizer Inc. (PFE) : Free Stock Analysis ...

Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.

Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer's decision to license SSGJ-707 doesn't make its stock a buy in and of itself. However, the drug candidate is another valuable asset that will be part of the company's plan to improve its ...